| 10.56 -0.2 (-1.86%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.98 |
1-year : | 15.17 |
| Resists | First : | 11.11 |
Second : | 12.98 |
| Pivot price | 10.04 |
|||
| Supports | First : | 9.53 |
Second : | 8.55 |
| MAs | MA(5) : | 10.27 |
MA(20) : | 9.88 |
| MA(100) : | 12.91  |
MA(250) : | 9.88 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.7 |
D(3) : | 71.6 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 18.67 | Low : | 3.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FTRE ] has closed below upper band by 24.1%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.13 - 11.18 | 11.18 - 11.23 |
| Low: | 10.3 - 10.36 | 10.36 - 10.4 |
| Close: | 10.47 - 10.57 | 10.57 - 10.64 |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Wed, 29 Apr 2026
Vanguard holds 4.73M shares in Fortrea Holdings (NASDAQ: FTRE) in 13G filing - Stock Titan
Tue, 28 Apr 2026
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance Singapore
Mon, 27 Apr 2026
Implied volatility surging for Fortrea Holdings stock options - MSN
Mon, 27 Apr 2026
[ARS] Fortrea Holdings Inc. SEC Filing - Stock Titan
Mon, 27 Apr 2026
Fortrea (NASDAQ: FTRE) sets 2026 director, auditor and Say-on-Pay votes - Stock Titan
Sun, 26 Apr 2026
Fortrea (FTRE) Q3 2024 earnings summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 10,310 (K) |
| Shares Short P.Month | 9,510 (K) |
| EPS | -10.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | -36.3 % |
| Operating Margin | 1.3 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | -102.5 % |
| Qtrly Rev. Growth | -5.2 % |
| Gross Profit (p.s.) | 5.38 |
| Sales Per Share | 29.09 |
| EBITDA (p.s.) | 0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 114 (M) |
| Levered Free Cash Flow | 196 (M) |
| PE Ratio | -0.98 |
| PEG Ratio | 0.3 |
| Price to Book value | 1.74 |
| Price to Sales | 0.36 |
| Price to Cash Flow | 8.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|